Home > Dermatology > AAD 2018 > Pearls of the posters > Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab

Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab

Presented By
Dr Jennifer Cather
Conference
AAD 2018
Trial
Aesthetics Center in Dallas, USA

Genital lesions are not rare in psoriasis; however, often overlooked is their severe impact on the patient’s QoL [2,3]. Psoriasis in this location is seen as especially embarrassing and is, moreover, often mistaken for a sexually transmitted disease [4].

A substantial proportion of patients experiences increased problems after sexual activity. In an observational, multicentre study of 354 participants, 87% reported itch, 39% pain, 42% dyspareunia, 32% a worsening of their genital psoriasis after intercourse, and 43% a decreased frequency of intercourse [5].

The current Phase 3b randomised controlled trial by Dr Jennifer Cather of the Aesthetics Center in Dallas and her colleagues therefore investigated whether treatment of genital psoriasis with the IL-17 blocker ixekizumab has a positive influence on the sexual activity of patients [6]. 149 participants were randomised to receive either a placebo over 12 weeks or 80 mg of ixekizumab subcutaneous every two weeks aft...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on